Clinical trial
Effects of CX516 on Functioning in Fragile X Syndrome and Autism
NCT00054730 · RespireRx, Industry · Completed
Key facts
| NCT number | NCT00054730 |
|---|---|
| Title | Effects of CX516 on Functioning in Fragile X Syndrome and Autism |
| Official title | Effects of Ampakine CX516 (Ampalex®) on Functioning in Fragile X Syndrome and Autism |
| Lead sponsor | RespireRx, Industry |
| Collaborators | FRAXA Research Foundation |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Fragile X Syndrome, Autism |
| Intervention type | Drug |
| Interventions | CX516 (Ampalex®) |
| Start date | Jun 1, 2002 |
| First posted | Feb 11, 2003 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: